Andrew W. Hahn, MD

Andrew W. Hahn, MD

Dr. Andrew Hahn is an Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center. Andrew earned a Bachelor of Arts in Synthetic Medicinal Chemistry and his Medical Doctorate at the University of Tennessee. Dr. Hahn completed Internal Medicine residency and a Chief Medicine Resident year at the University of Utah followed by his Medical Oncology fellowship at MD Anderson Cancer Center. His clinical focus is on prostate and kidney cancers. His research focus is to investigate how host factors influence response, resistance, and toxicity to cancer treatments and to design and run clinical trials to improve outcomes for patients with prostate and kidney cancer. Dr. Hahn has published over 40 peer-reviewed original research articles and authored or co-authored 30 other editorials, reviews, and book chapters. His work has been supported by an ASCO Conquer Cancer Foundation Young Investigator Award, Prostate Cancer Foundation Young Investigator Award, and a Department of Defense Early Investigator Research Award.

Talks by Andrew W. Hahn, MD

Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future Directions

Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future Directions

Posted by | Sep 2024

Andrew W. Hahn, MD, addresses cardiometabolic health in men with advanced prostate cancer, focusing on the impacts of hormone therapy and strategies for managing cardiovascular risks.

In this 10-minute talk, Dr. Hahn highlights the common overlap of prostate cancer and cardiometabolic risk factors and underscores the necessity of evaluating cardiovascular risk in prostate cancer patients. He reviews data indicating that androgen deprivation therapy (ADT) can indirectly increase cardiovascular risks by altering body composition and intensifying metabolic syndrome. Adding androgen receptors nearly doubles cardiovascular event risk. Despite FDA advisories, guidelines, and the availability of cardiovascular risk assessments, many patients undergoing ADT lack appropriate cardiovascular monitoring.

Dr. Hahn highlights future directions in identifying men at heightened risk for cardiovascular events using imaging and genomic biomarkers. Promising approaches include myocardial perfusion PET scans and exploring genomic markers that correlate with cardiovascular toxicity in hormone therapy. Managing cardiometabolic health in advanced prostate cancer requires careful risk assessment and personalized approaches. Biomarkers are needed to effectively predict cardiovascular complications from hormone therapy.

Read More
Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging

Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging

Posted by | Aug 2024

Andrew W. Hahn, MD, explores the treatment of oligometastatic prostate cancer in the context of advancements in PSMA PET imaging. Dr. Hahn examines the integration of systemic therapies with local treatments, discussing the benefits and challenges of combining androgen deprivation therapy (ADT) with newer agents like androgen receptor inhibitors and chemotherapy. The presentation also delves into the evolving role of PSMA-targeted radioligand therapy, outlining promising results from early-phase studies and ongoing research on this treatment modality.
A significant portion of the presentation is dedicated to the practical considerations and challenges associated with implementing PSMA PET imaging and MDT in clinical practice. Dr. Hahn addresses issues related to accessibility, cost, and the need for multidisciplinary collaboration to ensure the best patient outcomes.

Read More
Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate Cancer

Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate Cancer

Posted by | Jun 2024

Andrew W. Hahn, MD, analyzes systemic therapy choices for men with metastatic hormone-sensitive prostate cancer. His presentation delves into the critical factors influencing treatment decisions and the latest advancements in therapeutic options.
Dr. Hahn begins by outlining current systemic therapies, including androgen deprivation therapy (ADT) and its combination with other agents. By discussing the mechanisms of action and the efficacy of various therapeutic agents, Dr. Hahn provides a detailed examination of the available treatment options.
Dr. Hahn also addresses the role of personalized medicine in managing metastatic hormone-sensitive prostate cancer. He highlights the importance of genetic profiling and biomarker testing in tailoring treatment plans to individual patients.
Throughout the presentation, Dr. Hahn underscores the dynamic nature of prostate cancer treatment, with ongoing research continually informing and refining clinical practice.

Read More

Join the GRU Community

- Why Join? -